{
    "clinical_study": {
        "@rank": "78927", 
        "arm_group": [
            {
                "arm_group_label": "Arm I: metformin hydrochloride", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive metformin hydrochloride tablet 850 mg PO BID for 24 months on Arm I, which includes a 4-week ramp up of 850 mg PO QD."
            }, 
            {
                "arm_group_label": "Arm II: placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive placebo tablet PO QD BID for 12 months which includes a 4-week ramp up of 850 mg PO QD. Patients initially randomized to the placebo group (Arm II) may crossover to the metformin group (Arm I) for months 13-24."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase III trial studies metformin hydrochloride to see how well it works\n      compared to placebo in decreasing atypical cells in patients with atypical hyperplasia or in\n      situ breast cancer."
        }, 
        "brief_title": "Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer", 
        "condition": [
            "Atypical Ductal Breast Hyperplasia", 
            "BRCA1 Mutation Carrier", 
            "BRCA2 Mutation Carrier", 
            "Ductal Breast Carcinoma in Situ", 
            "Lobular Breast Carcinoma in Situ"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma in Situ", 
                "Carcinoma, Intraductal, Noninfiltrating", 
                "Hyperplasia", 
                "Carcinoma, Ductal, Breast", 
                "Carcinoma, Lobular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to 1 of 2 treatment groups. Patients will receive metformin\n      hydrochloride 850 mg by mouth (PO) twice daily (BID) for 24 months on Arm I, which includes\n      a 4-week ramp up of 850 mg PO QD. Patients will receive placebo 850 mg PO BID for 12 months\n      on Arm II, which includes a 4-week ramp up of 850 mg PO QD. Patients initially randomized to\n      the placebo (Arm II) may crossover to the metformin hydrochloride treatment group (Arm I)\n      for months 13-24.  The primary and secondary objectives are described below.\n\n      Primary Objective:\n\n      \u2022 Test for the presence or absence of cytological atypia in random periareolar fine needle\n      aspiration (RPFNA) bilateral aspirates for women receiving metformin versus placebo control.\n\n      Secondary Objectives:\n\n        -  Use the Masood Cytology Index Score to test for the presence of cytological atypia or\n           disappearance of cytological atypia in RPFNA bilateral aspirates.\n\n        -  Compare Masood Cytology Score values in the right and left breasts from the same\n           individual in the metformin and placebo groups.\n\n        -  Test the reproducibility of reverse phase protein microarray (RPPM) in duplicate RPPM\n           determinations from individual RPFNA specimens.\n\n        -  Correlate baseline RPPM values with presence of atypia (as measured by Masood Cytology\n           Index Score).\n\n        -  Determine the change in percent breast density.\n\n      After completion of study treatment, patients are followed up for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Pre-Registration Inclusion Criteria:\n\n          1. Must be at increased risk for breast cancer, defined as at least one of the following\n             four criteria:\u2028\n\n               -  Having had a prior biopsy demonstrating atypical hyperplasia, lobular carcinoma\n                  in situ (LCIS), or ductal carcinoma in situ (DCIS)\u2028\n\n               -  A Gail Model Risk of  \u22651.66% over 5 years\u2028\n\n               -  A strong family history of breast and/or ovarian cancer as defined in the study\n                  protocol.\n\n               -  Known breast cancer (BRCA)1 or BRCA2 mutation carrier providing that the woman\n                  has: \u2028\n\n                    -  Met with a genetic counselor to review genetic testing results, and \u2028\n\n                    -  Has been offered the opportunity to undergo prophylactic mastectomy and\n                       oophorectomy\n\n          2. Pre-menopausal women as defined as four menstrual cycles within the last six months\n             prior to pre-registration. Women with less than 4 menses within 6 months prior to\n             pre-registration or women who have had a hysterectomy with ovaries intact will be\n             considered premenopausal if follicle-stimulating hormone (FSH) level is < 20. Women\n             who are using hormonal contraceptives that cause amenorrhea (e.g. injectable and\n             extended oral contraceptives, Hormone-containing contraceptive ring, or\n             hormone-containing intrauterine device) will be considered eligible if they had a\n             minimum of 4 menstrual cycles within the last six months prior to starting on the\n             contraceptive.\n\n          3. Digital mammogram within 180 days prior to pre-registration.\n\n          4. Mammographic density \u2265 25% or mammogram evaluated by a radiologist as scattered fibro\n             glandular density.\n\n          5. Mammograms must be read as not suspicious for breast cancer (American College of\n             Rheumatology [ACR] class I-III). Subjects with a class IV mammogram may be enrolled\n             once they have been evaluated by a breast surgeon and there is no evidence of\n             invasive malignancy.\n\n          6. Must be non-pregnant and non-lactating for at least one year prior to\n             pre-registration.\n\n          7. If currently menstruating, subjects must use a reliable method of birth control.\n\n          8. Willing to provide RPFNA and blood samples for correlative research purposes.\n\n          9. Women with core biopsy or excisional biopsy containing DCIS, LCIS or atypia are\n             eligible for this study.\n\n         10. Women eligible to take tamoxifen must be offered tamoxifen prevention as part of\n             their clinical care and have refused tamoxifen treatment.\n\n         11. Age 25-55 years.\n\n        Pre-registration Exclusion Criteria:\n\n          1. Other active malignancy \u2264 5 years prior to pre-registration. EXCEPTIONS:\n             Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a\n             history of prior malignancy, they must not be receiving other specific treatment,\n             i.e., other hormonal therapy, for their cancer.\n\n          2. Body mass index (BMI) < 25.\n\n          3. Receiving warfarin.\n\n          4. Bilateral breast implants or autologous breast flap reconstruction.\n\n          5. Active diagnosis of alcoholism.\n\n          6. Contraindication to metformin prevention such as acute hypersensitivity or allergic\n             reaction to metformin.\n\n          7. Receiving tamoxifen or raloxifene.\n\n          8. Administration of any investigational agent \u2264 30 days prior to pre-registration.\n\n          9. Radiation to both breasts.\n\n         10. Co-morbid systemic illnesses or other severe concurrent disease which, in the\n             judgment of the investigator, would make the patient inappropriate for entry into\n             this study or interfere significantly with the proper assessment of safety and\n             toxicity of the prescribed regimens.\n\n         11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n         12. Receiving pyrimethamine, cimetidine, rifampin or cephalexin.\n\n         13. Women who have a core biopsy or excisional biopsy containing invasive cancer.\n\n        Registration/Randomization Inclusion Criteria:\n\n          1. Qualifying cytological atypia in RPFNA, Masood score of 14-17.\n\n          2. Required laboratory values obtained no more than 30 days prior to\n             registration/randomization.\n\n               1. Hemoglobin \u2265 9 g/dL.\n\n               2. Absolute neutrophil count (ANC) \u2265 1500/mm^3.\n\n               3. Platelet count \u2265 75,000/mm^3.\n\n               4. Creatinine \u2264 1.5 mg/dL or creatinine clearance (CrCl) >= 30 mL/min.\n\n               5. Total bilirubin \u2264 3.0 mg/dL.\n\n               6. Aspartate trasaminase (AST) \u2264 3 x upper limit of normal (ULN).\n\n               7. Alanine transaminase (ALT) \u2264 3 x ULN.\n\n          3. Negative pregnancy test done \u2264 7 days prior to registration /randomization, for women\n             of childbearing potential only."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905046", 
            "org_study_id": "A211102", 
            "secondary_id": [
                "U10CA031946", 
                "NCI-2013-00995"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I: metformin hydrochloride", 
                "description": "given PO", 
                "intervention_name": "metformin hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "1,1 - dimethylbiguanide hydrochloride", 
                    "657-24-9", 
                    "N, N - dimethylimidodicarbonimidic diamide monohydrochloride"
                ]
            }, 
            {
                "arm_group_label": "Arm II: placebo", 
                "description": "given PO", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "PLCB"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 18, 2013", 
        "number_of_arms": "2", 
        "official_title": "Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1,1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women", 
        "overall_official": {
            "affiliation": "Duke University School of Medicine - Department of Pharmacology and Cancer Biology", 
            "last_name": "Victoria Seewaldt, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Test for the presence or absence of atypia in RPFNA after 12 months and 24 months. Month 24 is optional for the placebo group for those patients who remain on the placebo arm and will not receive metformin (Metformin versus placebo control).", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905046"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Test for the Masood Score and the presence of atypia or disapperance of atypia in RPFNA after 12 months (for both arms) and 24 months for Metformin arm.", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Test the reproducibility of RPPM in duplicate RPPM determination from single bilateral RPFNA specimen.", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Determine the change in percent breast density from prior to the initiation of metformin or placebo treatment through therapy (ie, Months 12 and 24) and following therapy (Months 36 and 48).", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 48 months"
            }, 
            {
                "measure": "Compare Masood Cytology Score value at 0, 12 and 24 months in right and left breast from the same individual in the metformin and non-metformin group.", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Correlate baseline RPPM values with presence of atypia at Month 12 and Month 24.", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Alliance for Clinical Trials in Oncology", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Alliance for Clinical Trials in Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}